Full Press Release Details
STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) --Collegium Pharmaceutical, Inc.(Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website:www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website atwww.collegiumpharma.com.
Investor Contacts:Ian KarpHead of Investor Relationsir@collegiumpharma.com
Danielle JesseDirector, Investor Relationsir@collegiumpharma.com